Abstracts Archive - Page 1164 of 2425 - ACR Meeting Abstracts

Abstract Number: 2393 • 2018 ACR/ARHP Annual Meeting
Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?
Nini Kyvsgaard¹, Mikael Thastum², Torben Mikkelsen¹, Anne Estmann³ and Troels Herlin¹, ¹Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark, ²Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus C, Denmark, ³Department of Pediatric Rheumatology, H.C. Andersen's Children's Hospital, Odense, Denmark
Background/Purpose: Nausea to low-dose methotrexate (MTX) is a significant clinical challenge in the treatment of juvenile idiopathic arthritis (JIA). There exists a large inter-individual variation…
Abstract Number: 2394 • 2018 ACR/ARHP Annual Meeting
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
Juliana Brunelli¹, Clovis A Silva¹, Sandra G Pasoto², Carla GS Saad², Katia T. Kozu¹, Elaine P Leon², Margarete B Vendramini², Nicole Fontoura², Eloisa Bonfa³ and Nadia E Aikawa², ¹Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-adalimumab antibody (AAA) production may lead to reduced adalimumab (ADA) serum levels and therapy failure. There are, however, scarce and conflicting data regarding ADA…
Abstract Number: 2395 • 2018 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals
Daniel Groth¹, Maria Perez², Simona Nativ³, James R. Treat⁴, Leslie Castelo-Soccio⁴, Pamela F. Weiss⁵, Marissa J. Perman⁴ and Sivia Lapidus³, ¹Pediatrics, Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ⁴Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The development of psoriasis while on TNFi is a paradoxical effect of agents that treat psoriasis and is described in larger cohorts inflammatory bowel…
Abstract Number: 2396 • 2018 ACR/ARHP Annual Meeting
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Lisa Marshall⁴ and Heather Jones⁴, ¹Memorial University of Newfoundland, St John's, NF, Canada, ²IQVIA, Kanata, ON, Canada, ³Global Outcomes & Evidence, Pfizer, Collegeville, PA, ⁴Pfizer, Collegeville, PA
Background/Purpose: In Canada, the pediatric indications of etanercept (ETN) are active ankylosing spondylitis (AS), plaque psoriasis (PsO) and moderate to severely active juvenile idiopathic arthritis…
Abstract Number: 2397 • 2018 ACR/ARHP Annual Meeting
The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Kirsten Minden³, Pierre Quartier⁴, Jaclyn K. Anderson⁵, Kristina Unnebrink⁶, Ivan Lagunes Galindo⁵ and Gerd Horneff⁷, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Charite University Medicine, Berlin, Germany, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co., Ludwigshafen, Germany, ⁷Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany
Background/Purpose: Children with one or more subtypes of juvenile idiopathic arthritis, such as enthesitis-related arthritis (ERA), often exhibit growth impairments. The purpose of the analysis…
Abstract Number: 2398 • 2018 ACR/ARHP Annual Meeting
Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category
Dax G. Rumsey¹, Jaime Guzman², Alan Rosenberg³, Adam Huber⁴, Rosie Scuccimarri⁵, Natalie J. Shiff⁶, Alessandra Bruns⁷, Brian M. Feldman⁸ and Dean Eurich⁹, ¹Paediatrics, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, ⁶University of Florida, Gainesville, FL, ⁷Hospitalier de l’Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada
Background/Purpose: To estimate the impact of enthesitis on patient reported outcomes (PROs) in children with juvenile idiopathic arthritis (JIA), irrespective of their JIA category. Methods:…
Abstract Number: 2399 • 2018 ACR/ARHP Annual Meeting
Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Ciarán M. Duffy¹, Adam Baxter-Jones², Leanne Ward³, Heather Macdonald⁴, Heather McKay⁴, Marta Erlandson², Adam Huber⁵, Susanne Benseler⁶, Michele Gibbon⁷, Jaime Guzman⁸ and Lori Tucker⁸, ¹Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Alberta Children's Hospital, Calgary, AB, Canada, ⁷Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁸BC Children's Hospital, Vancouver, BC, Canada
Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children…
Abstract Number: 2400 • 2018 ACR/ARHP Annual Meeting
Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population
Tristan Scheer¹, Jens Klotsche², Claudio A. Len³ and Ivan Foeldvari⁴, ¹Asklepios Campus Hamburg, Semmelweis University Budapest, Hamburg, Germany, ²Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo,, Brazil, ⁴Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatologic disease in children and adolescents with a prevalence of 1:1000 children in Germany.…
Abstract Number: 2401 • 2018 ACR/ARHP Annual Meeting
The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
Anjali Sura¹, Stacey Fogarty-Brown² and Meredith Riebschleger³, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Pediatrics, University of Michigan, Ann Arbor, MI, ³Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI
Background/Purpose: The caregivers of children with juvenile idiopathic arthritis (JIA) frequently ask about the utility of dietary restrictions. Some patients and physicians report a good…
Abstract Number: 2402 • 2018 ACR/ARHP Annual Meeting
Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study
Daniel Whittingslow^1,2, Hyeon Ki Jeong³, Talia Gergely⁴, Lori Ponder⁴, Sampath Prahalad⁵, Omer Inan³ and Shelly Abramowicz⁶, ¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Pediatrics, Emory University, Atlanta, GA, ⁶Surgery, Emory University/Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: The temperomandibular joint (TMJ) is one of the most commonly affected joints in juvenile idiopathic arthritis (JIA) (up to 45% of cases). There is a discrepancy between…
Abstract Number: 2403 • 2018 ACR/ARHP Annual Meeting
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
Valérie Devauchelle-Pensec¹, Anne Lohse², Francis Guillemin³, Elisabeth Solau-Gervais⁴, Linda Rossi-Semerano⁵, Agnès Duquesne⁶, Irène Lemelle⁷, Pascal Pillet⁸, Claire Ballot⁹, Laurence Goumy¹⁰, Tu Anh Tran¹¹, Laeticia Sparsa¹², Heloise Reumaux¹³, Anaïs Arbault¹⁴ and Camille Alleyrat¹⁵, ¹Rheumatology, CHU Brest, Brest, France, ²Rheumatology Department, Hopital Nord Franche Comté, Belfort, France, ³Université de Lorraine, EA4360, APEMAC, Nancy, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁶4Department of Nephrology-Rheumatology-Dermatology Pediatric - Rheumatology, Hopital Femme-Mère-Enfant, Bron, France, ⁷Department of pediatric onco-hematology, CHU de Nancy - Hôpitaux de Brabois,, Vandœuvre-Lès-Nancy, France, ⁸Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, ⁹Department of Pediatric Rheumatology, Hôpital Jean-Minjoz, Besançon, France, ¹⁰Pediatric, CHU d'Angers, Angers, France, ¹¹Paediatrics, University Hospital, Nîmes, Nîmes, France, ¹²Rheumatology, Hopital Emile Muller, Mulhouse, France, ¹³Pediatric Rheumatology, CHRU Lille, Lille, France, ¹⁴Rheumatology, CHU de Dijon, Dijon, France, ¹⁵134 Inserm CIC-1433 Clinical Epidemiology, CHRU de Nancy, Hôpitaux de Brabois, Nancy, France
Background/Purpose: The therapeutic compliance (TC) is a major issue for the management of Juvenile Idiopathic Arthritis (JIA). The chronic nature of this inflammatory rheumatism requires…
Abstract Number: 2404 • 2018 ACR/ARHP Annual Meeting
Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment
W. Blaine Lapin¹, Taylor Phillips², Danielle Guttman-Lapin³, Amanda Brown⁴, Eyal Muscal⁵ and Filiz O. Seeborg¹, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Rice University, Houston, TX, ³Aldine Independent School District, Aldine, TX, ⁴Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Baylor College of Medicine, houston, TX, ⁵Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Patients with Juvenile Idiopathic Arthritis (JIA) face physical, social, and emotional issues that affect their quality of life. Health-related quality of life (HRQoL) is…
Abstract Number: 2405 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
Joseph McDonald¹, Curtis Travers², Courtney McCracken², Steven Yeh³, Kelly A. Rouster-Stevens⁴, Patricia Vega-Fernandez⁴, Elaine Ramsay⁴, Sampath Prahalad⁴, Carolyn Drews-Botsch⁵ and Sheila Angeles-Han⁶, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁶Rheumatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH
Background/Purpose: Pediatric chronic non-infectious uveitis can lead to ocular complications and vision loss. The ophthalmic clinical exam is primarily used to assess uveitis outcomes but…
Abstract Number: 2406 • 2018 ACR/ARHP Annual Meeting
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents
Andreas Reiff, Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Chronic uveitis is a common manifestation of pediatric rheumatologic conditions and may result in irreversible blindness and long term disability. While chronic anterior uveitis…
Abstract Number: 2407 • 2018 ACR/ARHP Annual Meeting
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Mikhail Kostik, Ekaterina Gaidar, Maria Likhacheva, Eugenia Isupova, Irina Chikova, Margarita Dubko, Vera Masalova, Tatiana Likhacheva, Ludmila Snegireva, Tatiana Kornishina, Olga Kalashnikova and Vyacheslav Chasnyk, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The most often prescribed biologics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].